Replimune: Multiple Shots On Goal But A High Risk Binary Approaches

Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See ...
Compare the Cloud

Vibe Coding With Cursor AI and Replit Agent — What a UK Business Owner With No Dev Skills Needs to Know Before Building an App

AI-generated. Cursor AI, Replit Agent, GitHub Copilot let non-devs build apps. Pricing, pitfalls, UK data protection rules — ...